No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world.

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.  Claims of lawsuits against Ozempic and similar drugs are indeed true.

In the past year or couple of years, you’ve likely heard a lot about Ozempic, most likely in the context of weight loss. Not for nothing — a lot of people turned to this diabetes medicine with the hopes that it would help them lose weight — and it did.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

The healthcare company will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications. Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service,

The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost controls amid challenges in the obesity-drug market.

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low. Denmark’s confidence index fell to -17.2 this month, according to official data – despite a backdrop of inflation-beating pay rises, low interest rates and a buoyant jobs market.